About the IOV-LUN-202 clinical trial

IOV-LUN-202 is currently enrolling adults across North America who have been diagnosed with histologically confirmed recurrent or metastatic NSCLC across 4 patient groups.

The investigational TIL therapy product (lifileucel)
is manufactured by IOVANCE Biotherapeutics.

The objective of the trial is to determine the safety and efficacy of TIL therapy based on:

• Tumor size reduction
• Slowing the progression of NSCLC
• Eliminating detectable NSCLC
• Extending the life of the patients without their cancer worsening